$308 Million is the total value of Euclidean Capital LLC's 14 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | Sell | PMV PHARMACEUTICALS INC | $133,520,000 | -2.9% | 3,908,677 | -6.5% | 43.34% | -5.8% |
| NGM | NGM BIOPHARMACEUTICALS INC | $29,449,000 | -32.2% | 1,493,349 | 0.0% | 9.56% | -34.2% | |
| DNLI | DENALI THERAPEUTICS INC | $25,395,000 | +37.4% | 323,749 | 0.0% | 8.24% | +33.3% | |
| RAPT | RAPT THERAPEUTICS INC | $23,391,000 | +43.2% | 735,801 | 0.0% | 7.59% | +38.9% | |
| ALEC | ALECTOR INC | $20,432,000 | +3.4% | 980,894 | 0.0% | 6.63% | +0.3% | |
| CNST | CONSTELLATION PHARMCETICLS I | $18,736,000 | +44.5% | 554,325 | 0.0% | 6.08% | +40.2% | |
| ORIC | ORIC PHARMACEUTICALS INC | $17,632,000 | -27.8% | 996,734 | 0.0% | 5.72% | -30.0% | |
| FHTX | FOGHORN THERAPEUTICS INC | $13,458,000 | -19.0% | 1,261,261 | 0.0% | 4.37% | -21.5% | |
| SNOW | New | SNOWFLAKE INCcl a | $11,397,000 | – | 47,136 | +100.0% | 3.70% | – |
| FFBC | FIRST FINL BANCORP OH | $4,102,000 | -1.5% | 173,576 | 0.0% | 1.33% | -4.5% | |
| NRIX | New | NURIX THERAPEUTICS INC | $4,097,000 | – | 154,426 | +100.0% | 1.33% | – |
| BEAM | BEAM THERAPEUTICS INC | $4,007,000 | +60.8% | 31,131 | 0.0% | 1.30% | +56.0% | |
| PDD | Buy | PINDUODUO INCsponsored ads | $1,246,000 | +13.9% | 9,806 | +20.0% | 0.40% | +10.4% |
| VIR | Buy | VIR BIOTECHNOLOGY INC | $1,223,000 | -7.8% | 25,866 | +0.0% | 0.40% | -10.6% |
| RUBY | Exit | RUBIUS THERAPEUTICS INC | $0 | – | -12,791 | -100.0% | -0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.